ArticleBMC infectious diseases2026
Epidemiological dynamics of respiratory tract infections in a major northern coastal city (Dalian), China, following the COVID-19 pandemic.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo elucidate the epidemiological characteristics, including population distribution, temporal patterns, and co-infection rates, of major respiratory pathogens circulating in China to provide evidence for precision prevention and clinical management of respiratory tract infections (RTIs).
methodsWe retrospectively analyzed nucleic acid test (NAT) data from 15,426 RTI patients at a university hospital in Dalian, China, between January 2023 and December 2024. Six key pathogens were assayed: Mycoplasma pneumoniae (MP), influenza A/B (Flu A/B), respiratory syncytial virus (RSV), adenovirus (ADV), and human rhinovirus (HRV). Positivity rates and seasonal patterns were statistically compared across different genders and age cohorts.
resultsThe overall pathogen positivity rate was 27.9%. MP (10.5%) and Flu A (7.3%) were the predominant causative agents. The overall positivity rate was significantly higher in females than males (29.3% vs. 26.7%; p = 0.022), and detection rates for MP, Flu A, and HRV also showed gender-specific differences (p < 0.05). The highest positivity rate was observed in the children’s group (1–12 years, 80.0%), with MP being the most dominant pathogen (51.3%). Conversely, Flu A predominated in adults and the elderly. Seasonal analysis revealed a “high in winter and low in summer” pattern overall. Flu A and RSV peaked during winter, while MP exhibited an atypical biannual peak in autumn. Co-infections were detected in 2.2% of patients. Among co-infected patients (n = 334), the most frequently observed patterns being Flu A/MP (15%) and HRV/MP (14%).
conclusionsThe prevalence of major respiratory pathogens in China demonstrates significant variations across age, gender, and seasonal dimensions. MP and Flu A are the primary etiological agents. These findings advocate for strengthened seasonal surveillance and targeted strategies, specifically focusing on MP in pediatric populations and Flu A in adults and the elderly, with intensive monitoring of Flu A and RSV during autumn and winter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.